Patents Represented by Attorney Michael P. Morris
  • Patent number: 8198308
    Abstract: The present invention encompasses compounds of general formula (1) wherein the groups R2 to R4, L, Q and n are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Steffen Steurer, Peter Ettmayer, Andreas Mantoulidis, Ioannis Sapountzis, Martin Steegmaier
  • Patent number: 8198458
    Abstract: Compounds of formula (I): wherein Ar, X, R1, R2, R3 and R4 are as defined herein. The compounds are useful as reverse transcriptase inhibitors against wild type and single or double mutant strains of HIV.
    Type: Grant
    Filed: February 3, 2009
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Patrick DeRoy, Anne-Marie Faucher, Alexandre Gagnon, Serge R. Landry, Sebastien Morin, Jeffrey O'Meara, Bruno Simoneau, Bounkham Thavonekham, Christiane Yoakim
  • Patent number: 8196578
    Abstract: Disclosed is an inhaler for administering a medicament in the form of inhalable substances, substance formulations, or substance mixtures, especially in the form of a powder as depicted in exemplary FIG. 1. Said inhaler comprises a housing (1) which is provided with an interior (18) for accommodating at least one capsule that is filled with the medicament. The housing (1) is coupled to a mouthpiece (5) while an actuator (12) encompassing at least one needle (13) is mounted so as to be movable towards the housing in order to open the capsule. The mouthpiece (5) is effectively connected to the actuator (12) in such a way that the needle (13) of the actuator (12) does not extend into the interior (18) for puncturing the capsule in an operational position of the mouthpiece (5).
    Type: Grant
    Filed: April 13, 2007
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Oliver Wendland
  • Patent number: 8197845
    Abstract: The invention relates to powdered preparations containing tiotropium for inhalation, processes for preparing them as well as their use in preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: June 12, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Mareke Hartig, Michael Trunk, Michael Walz
  • Patent number: 8193214
    Abstract: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.
    Type: Grant
    Filed: September 27, 2007
    Date of Patent: June 5, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stéphane De Lombaert, Michel Jose Emmanuel
  • Patent number: 8193188
    Abstract: Disclosed are pyridodihydropyrazinone compounds, processes for preparing them and their use as pharmaceutical compositions. The compounds according to the invention correspond to general formula (I), while the groups L, R1, R2, R3, R4 and R5 may have the meanings given in the claims and specification.
    Type: Grant
    Filed: October 14, 2009
    Date of Patent: June 5, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Matthias Hoffmann, Matthias Grauert, Trixi Brandl, Martin Steegmaier, Rudolf Hauptmann
  • Patent number: 8188274
    Abstract: The invention relates to an improved process for preparing aminocrotonylamino-substituted quinazoline derivatives of general formula (I) wherein the groups Ra, Rb, Rc and Rd have the meanings given in the claims, as well as sulphonyl derivatives of formula and the use thereof as synthesis components for preparing quinazolines of formula (I). The quinazoline derivatives of formula (I) are inhibitors of signal transduction mediated by tyrosinekinases and by the Epidermal Growth Factor-Receptor (EGF-R) and are therefore particularly suitable for the treatment of tumoral diseases.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 29, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Juergen Schroeder, Georg Dziewas, Thomas Fachinger, Burkhard Jaeger, Cartsen Reichel, Svenja Renner
  • Patent number: 8188086
    Abstract: The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallization in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.
    Type: Grant
    Filed: September 17, 2008
    Date of Patent: May 29, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Guenter Linz, Peter Sieger, Matthias Grauert, Rolf Schmid
  • Patent number: 8178541
    Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: May 15, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Matthias Eckhardt, Michael Mark, Roland Maier, Ralf Lotz, Mohammad Tadayyon
  • Patent number: 8178111
    Abstract: The present invention relates to the field of animal health and in particular of Equine Herpes Viruses (EHV) wherein the gene encoding the protein gM is absent, and which is free of heterologous elements. Further aspects of the invention relate to pharmaceutical compositions comprising said viruses, uses thereof, and methods for the prophylaxis and treatment of EHV infections. The invention also relates to pharmaceutical compositions comprising the combination of EHV-1 and EHV-4 viruses wherein the gene encoding the protein gM is absent and which is free of heterologous elements.
    Type: Grant
    Filed: February 25, 2009
    Date of Patent: May 15, 2012
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Antonie Neubauer, Christine Ziegler
  • Patent number: 8178568
    Abstract: Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: May 15, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: John Regan, Doris Riether
  • Patent number: 8173699
    Abstract: Compounds of formula 1 and hetero derivatives thereof and the pharmacologically acceptable salts, enantiomers, racemates, hydrates, or solvates thereof, which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: May 8, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Horst Dollinger, Rolf Goeggel, Birgit Jung, Joerg Kley, Jurgen Mack, Peter Nickolaus, Rainer Walter
  • Patent number: 8175843
    Abstract: Computer-implemented methods for statistical analysis and summarization of a stability study on a pharmaceutical product using of a macro integrated into statistical analysis software. The method includes inputting and summarizing data observed for a stability study on a pharmaceutical product, statistically analyzing the data, including using at least one regression function to characterize the time-response relationship of at least one stability response variable, to estimate a shelf life of the pharmaceutical product or confirm the shelf life of an existing pharmaceutical product, and providing standardized output data and graphical presentations of observed stability response data. Also, a computer loaded with a general statistical analysis software and a macro integrated with the software such that the computer is capable of performing these computer-implemented methods using the software and macro.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: May 8, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Rene Kubiak, James Schwenke, Volker Krzykalla, Hans-Juergen Lomp, Cornelia Schepers
  • Patent number: 8173638
    Abstract: Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.
    Type: Grant
    Filed: November 15, 2007
    Date of Patent: May 8, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Angela Berry, Pier Francesco Cirillo, Eugene Richard Hickey, Doris Riether, David Smith Thomson, Lifen Wu
  • Patent number: 8168752
    Abstract: The present invention relates to mouse and human J12 polynucleotides, polypeptide and anti J12 antibody molecules. The J12 is a cytokine that is preferentially expressed in Th2 cells. The polypeptides and/or antibodies described herein can be used in methods for detection and treatment of certain autoimmune and inflammatory diseases including asthma.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: May 1, 2012
    Assignee: Boehringer Ingelheim Pharmaceutical, Inc.
    Inventors: Jianfei Yang, Frank James King, Jun Li, Zhenhao Qi, Ming Xue
  • Patent number: 8163911
    Abstract: The invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparing a medicament for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 24, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Elke Langkopf, Alexander Pautsch, Corinna Schoelch, Annette Schuler-Metz, Ruediger Streicher, Holger Wagner
  • Patent number: 8163918
    Abstract: Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: April 24, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Daniel Kuzmich, John Lord, Can Mao
  • Patent number: 8158633
    Abstract: The invention relates to novel phenyl-substituted pyrazolopyrimidines, process for their preparation, and their use for producing medicaments for improving perception, concentration, learning and/or memory.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: April 17, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Martin Hendrix, Frank-Gerhard Böβ, Nils Burkhardt, Christina Erb, Adrian Tersteegen, Marja Van Kampen
  • Patent number: 8158641
    Abstract: The present invention relates to 2-arylamino-4-(aminoalkylene)aminopyrimidines inhibitors having the structure shown below: wherein R and R1 are as defined herein. The 2-arylamino-4 -(aminoalkylene)aminopyrimidines inhibit Protein Kinase C-alpha (PKC-?). The PKC-? inhibitors of the present invention are important for improving myocardial intracellular calcium cycling, resulting in improved myocardial contraction and relaxation performance and thereby slowing the progression of heart failure. The present invention further relates to compositions comprising said 2-arylamino-4 -(aminoalkylene)amino-pyrimidines and to methods for controlling, abating, or otherwise slowing the progression of heart failure.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: April 17, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jane Far-Jine Djung, Adam Golebiowski, Jack A. Hunter, Gary P. Schrum
  • Patent number: RE43431
    Abstract: A compound of general formula I wherein: Ra is a benzyl, 1-phenylethyl, or 3-chloro-4-fluorophenyl group; Rb is a dimethylamino, N-methyl-N-ethylamino, diethylamino, N-methyl-N-isopropylamino, N-methyl-N-cyclopropylamino, N-methyl-N-(2-methoxyethyl)amino, N-ethyl-N-(2-methoxyethyl)amino, bis(2-methoxyethyl)amino, morpholino, N-methyl-N-(tetrahydrofuran-3-yl)amino, N-methyl-N-(tetrahydrofuran-2-ylmethyl)amino, N-methyl-N-(tetrahydrofuran-3-ylmethyl)amino, N-methyl-N-(tetrahydropyran-4-yl)amino, or N-methyl-N-(tetrahydropyran-4-ylmethyl)amino group; and Rc is a cyclopropylmethoxy, cyclobutyloxy, cyclopentyloxy, tetrahydrofuran-3-yloxy, tetrahydrofuran-2-ylmethoxy, tetrahydrofuran-3-ylmethoxy, tetrahydropyran-4-yloxy, or tetrahydropyran-4-ylmethoxy group, or a tautomer, stereoisomer, or salt thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibitory effect on signal transduction med
    Type: Grant
    Filed: August 18, 2009
    Date of Patent: May 29, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Frank Himmelsbach, Elke Langkopf, Stefan Blech, Birgit Jung, Anke Baum, Flavio Solca